Inflammatory Bowel Disease (IBD) Clinical Trial
Official title:
Translating Scientific Evidence Into Practice Using Digital Medicine and Electronic Patient Reported Outcomes
Delivery of healthcare has been traditionally limited to in-person visits or hospitalizations, while patients spend the majority of their time at home or work. Digital Medicine (e.g. apps, remote monitoring, telemedicine, patient reported outcomes) has the potential to bridge this gap, but the question remains as to how to translate it to mainstream practice while providing individualized recommendations to improve population health across organizations. Through the creation of a Digital Transformation Network (DTN) for Inflammatory Bowel Disease (IBD), the study team plans to reduce digital disparities and scientifically test the impact of these technologies in a clinical trial in three CTSA sites catering to diverse populations and communities.
Status | Recruiting |
Enrollment | 1578 |
Est. completion date | September 30, 2025 |
Est. primary completion date | June 30, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patients with confirmed Inflammatory Bowel Disease (IBD) will be enrolled into DTN in stepped-wedge cluster randomized trial - Age greater than or equal to 18 years - Ability to speak or understand English or Spanish Language. Exclusion Criteria: - Condition or disease that, in the opinion of the investigators, may make it exceedingly difficult for the patient to use DTN, including, but not limited to, advanced dementia. |
Country | Name | City | State |
---|---|---|---|
United States | Northwestern University | Chicago | Illinois |
United States | Cleveland Clinic | Cleveland | Ohio |
United States | University of California, Davis | Davis | California |
United States | Icahn School of Medicine at Mount Sinai | New York | New York |
United States | RxHealth | Secaucus | New Jersey |
Lead Sponsor | Collaborator |
---|---|
Icahn School of Medicine at Mount Sinai | Northwestern University, RxHealth, The Cleveland Clinic, University of California, Davis |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants in Disease Control | Number of participants in disease control. Disease control is defined by normalization of inflammatory markers and ePROs (PRO2<8 and PRO3<13). PRO2 measures stool frequency and bleeding while PRO3 measures the number of liquid or soft stools, abdominal pain and general well-being. Inflammatory markers including Erythrocyte Sedimentation Rate (ESR), C-Reactive Protein (CRP) and Fecal Calprotectin will be dichotomized using cut-offs of <30mm/hr, <5mg/L and <50 µg/g respectively for normal values. | 1 year after enrollment | |
Primary | Change in Number of Unplanned Acute Care | Change in number of unplanned acute care 1 year after enrollment as compared to baseline. Unplanned acute care is defined as the number of ED visits and hospitalizations days 12 months before the intervention and the last 12 months of DTN intervention. | baseline | |
Secondary | Northstar Digital Literacy Assessment | Digital skills and connectivity will be assessed using the Northstar digital literacy assessment. A 17-item rating scale, with full score from 0 to 100, with score 85% or above achieve a passing score. | 1 year after enrollment | |
Secondary | Digital Disparities Module | The digital disparities module is still in development through SBIR. The digital disparities module will assess the impact of digital disparities module in improving digital skills and access to Internet using previously developed digital disparities assessment instrument. The scale for the digital disparities assessment full scale from 0 - 100 where a higher score indicates the patient has a higher level of disparity in digital connectivity, digital skills and digital usage. | 1 year after enrollment | |
Secondary | Overall Health Numeric Rating Scale [OHNRS] | Overall Health Numeric Rating Scale (OHNRS) - Full scale from 0 to 10, higher score indicates worse health outcomes | 1 year after enrollment | |
Secondary | PROMIS Global scales | PROMIS Global scales is a 14-item measure that is part of the PROMIS Social Function. The measure refers to social roles, such as work and family responsibilities, and more discretionary social activities, such as leisure activity and relationships with friends. standardized to the general population, using the "T-Score". The average "T-Score" for the United States population is 50 points, with a standard deviation of 10 points. Higher scores indicate a healthier patient. | 1 year after enrollment | |
Secondary | Patient Health Questionnaire (PHQ-4) | The Patient Health Questionnaire (PHQ)-4 s a 4 item inventory. Anxiety subscale from 0-6, depression subscale from 0-6, with full scale from 0-12, higher score indicates more symptoms. | 1 year after enrollment | |
Secondary | Patient Health Questionnaire (PHQ-9) | The Questionnaire Type 9 for Depression (PHQ-9) is a self-administered instrument. Full scale from 0-27, with higher score indicating more severe symptoms. As needed. | 1 year after enrollment | |
Secondary | Generalized Anxiety Disorder scale (GAD-7) | The General Anxiety Disorder 7-item questionnaire (GAD-7) is a 7-item questionnaire. Full scale from 0-21, with higher score indicating more symptoms. As needed. | 1 year after enrollment | |
Secondary | Number of participants with improvement in mucosal healing | This will be defined as the absence of inflammation on endoscopy (scoring systems) or imaging notes collected from EHR. | 1 year after enrollment | |
Secondary | Visual Analog Scale (VAS) | The Visual Analog Scale (VAS) will be used to assess medication adherence using <80% cut-off to designate non-adherence. Full Scale from 0 to 100 with higher score indicating more adherence. | 1 year after enrollment | |
Secondary | Proportion of patients meeting eligible quality metrics | Proportion of patients meeting eligible quality metrics confirmed through EHR. Composite score of metrics for skin care protection, flu vaccination, smoking cessation advice, pneumonia vaccination, bone density test, hepatitis B screen steroid sparing medication, TB test and TPMT test | 1 year after enrollment | |
Secondary | System Usability Scale (SUS) | The system usability scale (SUS) is a 10-item Likert scale questionnaire. The range of scores is from 0 - 100 where a SUS score above 68 is considered average. | 1 year after enrollment | |
Secondary | Net Promoter Score | The Net Promoter is a 10 point scale and the full score ranges from -100 to 100 where a higher score translates to higher satisfaction with a product. | 1 year after enrollment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05428345 -
A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
|
||
Completed |
NCT02265588 -
Healthy Approach to Physical and Psychological Problems in Youngsters With IBD (HAPPY-IBD).
|
N/A | |
Completed |
NCT01022749 -
Efficacy Safety Study of Flu Vaccine in Immunodepression Patients
|
Phase 3 | |
Completed |
NCT02461758 -
Trial of High Dose vs. Standard Dose Influenza Vaccine in Inflammatory Bowel Disease Patients
|
Phase 4 | |
Completed |
NCT01095042 -
Cognition and Emotion in the SII and IBD
|
N/A | |
Completed |
NCT00542776 -
Impact of Immunosuppression in IBD Patients on Response to Influenza Vaccine
|
N/A | |
Completed |
NCT02778464 -
Faecal Calprotectin as a Potential Non-invasive Inflammatory Marker in Pregnancy and Inflammatory Bowel Disease
|
||
Completed |
NCT02256605 -
Vitamin D3 Supplementation in Pediatric IBD: Weely vs Daily Dosing Regimens
|
N/A | |
Recruiting |
NCT05078879 -
Empagliflozin as a Treatment for Severe Congenital Neutropenia Due to G6PC3 Deficiency
|
Phase 1 | |
Completed |
NCT05596422 -
A Study of Vedolizumab and Biologic Agents in Participants With Inflammatory Bowel Disease (IBD)
|
||
Completed |
NCT02355834 -
Faecal Incontinence iNtervention Study
|
N/A | |
Not yet recruiting |
NCT01852097 -
An Online Intervention to Address Barriers to IBD Medication Adherence
|
N/A | |
Terminated |
NCT00325078 -
Infliximab to Treat Crohn'S-like Inflammatory Bowel Disease in Chronic Granulomatous Disease
|
Phase 1/Phase 2 | |
Terminated |
NCT03886753 -
Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Ilera Specific Products
|
||
Completed |
NCT01819766 -
Detection of Advanced Colorectal Neoplasia by Stool DNA in Inflammatory Bowel Disease
|
N/A | |
Completed |
NCT01560819 -
Gut Microbial Transplantation in Pediatric Inflammatory Bowel Diseases
|
Phase 1 | |
Completed |
NCT00820365 -
SC12267 (4SC-101) for Treatment of Patients With Inflammatory Bowel Disease
|
Phase 2 | |
Completed |
NCT02156557 -
Study of KCC Peptide Application in the Colon
|
Phase 1 | |
Completed |
NCT01364896 -
Anal Human Papillomavirus in Inflammatory Bowel Disease Study
|
||
Terminated |
NCT00152620 -
Dexamethasone Versus Methylprednisolone for the Treatment of Active Inflammatory Bowel Disease
|
N/A |